N/A N=38 Strength Training for Skeletal Muscle Adaptation After Stroke
Stroke
Primary: Change in 1-repetition Maximum (RM) Muscle Strength (Leg Press, Paretic Side) — 126.1; 11.3 lbs
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Regulation of Muscle Protein Phenotype in Humans With Obesity
Obesity
Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr
N/A N=16 Effect of Exercise on the Human Skeletal Muscle Phosphoproteome
Skeletal Muscle Protein Synthesis
Primary: Change in Acute Muscle Protein Synthesis — 143; 123 percent change
N/A N=22 Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male
Hypogonadism, Male · Physical Activity · Testosterone Deficiency
Primary: Change From Baseline in Lean Mass — 2734; 499; 2268 grams
N/A N=71 Musculoskeletal Plasticity After Spinal Cord Injury
Spinal Cord Injuries
Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001
N/A N=8 7 Tesla MRI Study in Patients With Statin Related Muscle Complaints
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
N/A N=23 Validation of a Digital Twin Performing Strength Training
Healthy
Primary: Stop-and-go (SAG) Ability — -0.04 Time (s)
N/A N=33 Novel Intervention to Influence Muscle Plasticity in Veterans
Spinal Cord Injuries
Primary: HF Muscle Force — 23.9; 30.9 Newtons (N)
N/A N=52 Lower Extremity Muscle and Function in the Elderly: Study 2
Mobility Limitation
Primary: Leg Extensor Muscle Power — 32.9; 41.6 Watts
N/A N=17 Musculotendinous Tissue Repair Unit and Reinforcement (MTURR)
Traumatic Injury · Muscle Injury · Tendon Injury
Primary: Percent Change From Baseline in the Rectified and Integrated EMG Signal of the Tibialis Anterior Muscle At 24 Weeks Post-Operative — 1333 % change
N/A N=12 Progressive Strength Training in Spinal Muscular Atrophy
Muscular Atrophy, Spinal
Primary: Strength — 0.39 kilograms
N/A N=9 Translational Control of Anabolic Resistance in Aging Muscle
Physical Inactivity
Primary: Lean Mass — 403 grams
N/A N=58 Molecular Mechanisms of Exercise Benefits to Insulin Resistant People
Insulin Resistance · Obesity
Primary: Change in Muscle Strength — 0.37; -0.2 Ratio
N/A N=44 Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
Sarcopenia · Aging · Immune Function
Primary: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine) — 63.1; 63.2 units per ml — p=>0.05
N/A N=16 Functional Change With MMS
Muscle Weakness
Primary: Change in Body Satisfaction Questionnaire From Baseline to 1-month Post-Treatment Follow-up Visit — 8.6 units on a scale
N/A N=30 MoveStrong at Home: A Feasibility Study of a Model for Remote Delivery of Functional Strength and Balance Training Combined With Nutrition Education for Older Pre-frail Adults.
Arthritis · Cancer · Cardiovascular Diseases
Primary: Recruitment — 30 Participants
Early Phase 1 N=109 Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)
Aging
Primary: Percent Change in Type 2 Myofiber Cross Sectional Area — 18.5; 14.5 Percent change
N/A N=86 Comparison of Repetitive Magnetic Stimulation and Exercise on Quadriceps Function in COPD
Chronic Obstructive Pulmonary Disease
Primary: Quadriceps Fibre Size of Type IIa Fibres — 3885; 4326; 3610 micrometers squared
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
N/A N=38 Training Induced Muscle Exosome Release
Metabolism
Primary: miR-1 Abundance — 226; 110; 286 percent change
Phase 2 N=3 Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: Number of Dose Limiting Toxicity (DLT) Adverse Events as Assessed by 21 CFR 312.32. — 0 Number of Events
Phase 1 N=58 Phase 1 Study of ACE-083 in Healthy Subjects
Musculoskeletal Diseases
Primary: ACE-083 Safety and Tolerability: Number of Subjects With Adverse Events — 6; 6; 6; 6 Participants
Phase 2 N=12 Testosterone and Long Pulse Stimulation After SCI
Spinal Cord Injury
Primary: Muscle Size Change — 47.76; 31.1; 52.4; 36.0 Muscle CSA (cm^2)
Phase 2 N=37 A Study of Muscle Strength Maintenance in Older Adults
Sarcopenia
Primary: Change From Baseline in Isokinetic Strength — -4.90; -4.73 Newton — p=0.97
Phase 3 N=34 Strength Training in Walking Tolerance in Intermittent Claudication Patients
Peripheral Arterial Disease · Hypertension · Diabetes
Primary: Total Walking Distance — 618; 572 meter — p=<0.05
N/A N=19 Modulation of Motor Cortex Excitability by TMS and tDCS (MAGS1)
Motor Activity · Motor Neuroplasticity
Primary: Changes in Motor-evoked Potentials Ratios — 1.32; 0.73; 1.03 Ratio (unit: uV)
N/A N=51 Marijuana Use, Strength Training, and Alcohol Consumption (MUSTAC) Study
Chronic Pain
Primary: Alcohol Demand: Breakpoint — -6.00; -2.07; -1.81; -1.09 dollars/drink — p=.26
Phase 2 N=56 Power Training Post-stroke
Stroke
Primary: Gait Speed — 0.51 meters per second
N/A N=30 Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke
Stroke
Primary: Oxygen Consumption During Walking — 11.25; 4.46 ml/kg/min
Phase 4 N=34 Effect of Vitamin D Supplementation on Muscle Mass and Function
Obesity · Insulin Resistance · Inflammation
Primary: Muscle Function — 1.14; 1.50 kilograms